Showing results (71-80 of 129) with videos related to
Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|September 14, 2019
Superior skin cancer classification by the combination of human and artificial intelligenceAchim Hekler, Jochen S Utikal, Alexander H Enk, et al.Nature Biotechnology|May 23, 2024
Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screensZachary H Walsh, Parin Shah, Neeharika Kothapalli, et al.Nature Cancer|January 10, 2024
LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cellsDhiraj Kumar, Sreeharsha Gurrapu, Yan Wang, et al.Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.International Journal of Radiation Oncology, Biology, Physics|February 15, 2020
Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain MetastasesDaniel A Pomeranz Krummel, Tahseen H Nasti, Benjamin Izar, et al.Journal of Personalized Medicine|May 27, 2025
Central Nervous System Metastases from Primary Lung Carcinoma: Significance of RNA Fusion Testing and Early Versus Late MetastasesMichelle Garlin Politis, Mahesh Mansukhani, Benjamin O Herzberg, et al.The Oncologist|September 29, 2025
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patientsTristan L Lim, Kamaneh Montazeri, Eric Wehrenberg-Klee, et al.The Journal of Investigative Dermatology|September 26, 2024
Unveiling Common Transcriptomic Features between Melanoma Brain Metastases and Neurodegenerative DiseasesIrene Soler-Sáez, Alcida Karz, Marta R Hidalgo, et al.BMC Genomics|April 26, 2012
Comparative genomics and transcriptomics of lineages I, II, and III strains of Listeria monocytogenesTorsten Hain, Rohit Ghai, André Billion, et al.Journal for Immunotherapy of Cancer|December 25, 2024
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findingsBrian S Henick, Peter D Koch, Justin F Gainor, et al.Pageof 13